Please use this identifier to cite or link to this item:
Title: Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain
Author: Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Vargas, Diego
Bijedic, Adi
Keywords: Administració de medicaments
Malalties pulmonars obstructives cròniques
Tractament tèrmic
Economia de la salut
Administration of drugs
Chronic obstructive pulmonary diseases
Heat treatment
Medical economics
Issue Date: Feb-2017
Publisher: Dove Medical Press
Abstract: The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...
Note: Reproducció del document publicat a:
It is part of: Clinicoeconomics and Outcomes Research, 2017, vol. 9, num. February, p. 127-137
Related resource:
ISSN: 1178-6981
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
668396.pdf204.4 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons